These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11936708)

  • 1. A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis.
    Cremers S; Sparidans R; den HJ; Hamdy N; Vermeij P; Papapoulos S
    Eur J Clin Pharmacol; 2002 Feb; 57(12):883-90. PubMed ID: 11936708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.
    Pillai G; Gieschke R; Goggin T; Jacqmin P; Schimmer RC; Steimer JL
    Br J Clin Pharmacol; 2004 Dec; 58(6):618-31. PubMed ID: 15563360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
    Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
    J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short term whole body retention in relation to rate of bone resorption and cartilage degradation after intravenous bisphosphonate (pamidronate) in rheumatoid arthritis.
    Cremers SC; Lodder MC; Den Hartigh J; Vermeij P; Van Pelt P; Lems WF; Papapoulos SE; Dijkmans BA
    J Rheumatol; 2004 Sep; 31(9):1732-7. PubMed ID: 15338492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study.
    Gallacher SJ; Fenner JA; Anderson K; Bryden FM; Banham SW; Logue FC; Cowan RA; Boyle IT
    Thorax; 1992 Nov; 47(11):932-6. PubMed ID: 1465751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uninterrupted oral bisphosphonate (pamidronate) therapy of patients with osteoporosis is not associated with chronic stimulation of parathyroid hormone secretion.
    Landman JO; Papapoulos SE
    Osteoporos Int; 1995 Mar; 5(2):93-6. PubMed ID: 7599454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis.
    Cremers SC; Pillai G; Papapoulos SE
    Clin Pharmacokinet; 2005; 44(6):551-70. PubMed ID: 15932344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.
    Vis M; Bultink IE; Dijkmans BA; Lems WF
    Osteoporos Int; 2005 Nov; 16(11):1432-5. PubMed ID: 15883662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonate therapy.
    Licata AA
    Am J Med Sci; 1997 Jan; 313(1):17-22. PubMed ID: 9001162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.
    Bauss F; Russell RG
    Osteoporos Int; 2004 Jun; 15(6):423-33. PubMed ID: 15205712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis.
    Heijckmann AC; Juttmann JR; Wolffenbuttel BH
    Neth J Med; 2002 Sep; 60(8):315-9. PubMed ID: 12481878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of intravenous pamidronate to standard therapy for osteoporosis: use in patients unable to take oral bisphosphonates.
    Miller RG; Chretien KC; Meoni LA; Liu YP; Klag MJ; Levine MA
    J Clin Rheumatol; 2005 Feb; 11(1):2-7. PubMed ID: 16357689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of different markers of bone resorption in postmenopausal osteoporotic women treated with pamidronate.
    Kollerup G; Sørensen HA; Hyldstrup L; Storm T
    Scand J Clin Lab Invest; 1997 Oct; 57(6):479-86. PubMed ID: 9350066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a rat model for the simultaneous assessment of pharmacokinetic and pharmacodynamic aspects of bisphosphonate treatment: application to the study of intravenous 14C-labeled 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate.
    Koopmans SJ; van der Wee-Pals L; Löwik CW; Papapoulos SE
    J Bone Miner Res; 1994 Feb; 9(2):241-6. PubMed ID: 8140937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment for osteoporosis in people with ß-thalassaemia.
    Bhardwaj A; Swe KM; Sinha NK; Osunkwo I
    Cochrane Database Syst Rev; 2016 Mar; 3():CD010429. PubMed ID: 26964506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis.
    Reginster JY; Gieschke R
    Curr Drug Metab; 2006 Oct; 7(7):827-36. PubMed ID: 17073582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pamidronate: A model compound of the pharmacology of nitrogen-containing bisphosphonates; A Leiden historical perspective.
    Papapoulos SE
    Bone; 2020 May; 134():115244. PubMed ID: 31958532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term effects of pamidronate on biochemical markers of bone metabolism in osteoporosis--a placebo-controlled dose-finding study.
    Mallmin H; Ljunghall S; Larsson K; Lindh E
    Ups J Med Sci; 1991; 96(3):205-12. PubMed ID: 1810080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recovery of serum calcium concentrations following acute hypocalcemia in patients with osteoporosis on long-term oral therapy with the bisphosphonate pamidronate.
    Landman JO; Schweitzer DH; Frölich M; Hamdy NA; Papapoulos SE
    J Clin Endocrinol Metab; 1995 Feb; 80(2):524-8. PubMed ID: 7852514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.